{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:52:31Z","timestamp":1790837551145,"version":"4.1.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Clinique et Biologique"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.tracli.2011.02.021","type":"journal-article","created":{"date-parts":[[2011,4,4]],"date-time":"2011-04-04T12:05:29Z","timestamp":1301918729000},"page":"235-245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Allogreffes de cellules souches h\u00e9matopo\u00ef\u00e9tiques"],"prefix":"10.1016","volume":"18","author":[{"given":"M.","family":"Michallet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tracli.2011.02.021_bib0005","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/35077246","article-title":"Progress in human tumour immunology and immunotherapy","volume":"411","author":"Rosenberg","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.tracli.2011.02.021_bib0010","first-page":"771","article-title":"Tumor antigens recognized by T-lymphocytes in human cancers. New advances and therapeutic perspectives","volume":"46","author":"Gaugler","year":"1998","journal-title":"Pathol Biol (Paris)"},{"key":"10.1016\/j.tracli.2011.02.021_bib0015","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/35077251","article-title":"Haematopoietic cell transplantation as immunotherapy","volume":"411","author":"Appelbaum","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.tracli.2011.02.021_bib0020","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood.V57.2.267.267","article-title":"Chronic graft-versus-host disease in 52\u00a0patients: adverse natural course and successful treatment with combination immunosuppression","volume":"57","author":"Sullivan","year":"1981","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2011.02.021_bib0025","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/S0140-6736(95)90978-8","article-title":"Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis","volume":"345","author":"Blaise","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.tracli.2011.02.021_bib0030","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0140-6736(87)90763-X","article-title":"Impact of T-cell depletion on outcome of allogeneic bone marrow transplantation for standard-risk leukaemias","volume":"2","author":"Maraninchi","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.tracli.2011.02.021_bib0035","doi-asserted-by":"crossref","first-page":"806","DOI":"10.7326\/0003-4819-108-6-806","article-title":"Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion","volume":"108","author":"Goldman","year":"1988","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.tracli.2011.02.021_bib0040","doi-asserted-by":"crossref","first-page":"646","DOI":"10.7326\/0003-4819-120-8-199404150-00004","article-title":"Identical-twin bone marrow transplants for leukemia","volume":"120","author":"Gale","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.tracli.2011.02.021_bib0045","first-page":"150","article-title":"Prospective randomized study of GVHD prevention using an anti-IL2\u00a0receptor (CD25) MoAb after allogeneic bone marrow transplantation (BMT)","volume":"7","author":"Blaise","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.tracli.2011.02.021_bib0050","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0140-6736(93)92526-Y","article-title":"Long-term follow-up of T-cell depletion for bone marrow transplantation","volume":"341","author":"Blaise","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.tracli.2011.02.021_bib0055","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia","volume":"86","author":"Kolb","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2011.02.021_bib0060","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.1999.17.4.1234","article-title":"Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies","volume":"17","author":"Porter","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tracli.2011.02.021_bib0065","first-page":"1130","article-title":"Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia?","volume":"111","author":"Ringden","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tracli.2011.02.021_bib0070","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1073\/pnas.0337543100","article-title":"Definitive separation of graft-versus-leukemia - and graft-versus-host - specific CD4+ T cells by virtue of their receptor beta loci sequences","volume":"100","author":"Michalek","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tracli.2011.02.021_bib0075","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1051\/medsci\/2003195540","article-title":"Can one separate GVH and GVT after allogenic hematopoietic stem cell transplantation?","volume":"19","author":"Mohty","year":"2003","journal-title":"Med Sci (Paris)"},{"key":"10.1016\/j.tracli.2011.02.021_bib0080","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0301-472X(00)00540-3","article-title":"Current status of umbilical cord blood hematopoietic stem cell transplantation","volume":"28","author":"Gluckman","year":"2000","journal-title":"Exp Hematol"},{"key":"10.1016\/j.tracli.2011.02.021_bib0085","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJM199810223391702","article-title":"Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype","volume":"339","author":"Aversa","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2011.02.021_bib0090","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1182\/blood.V86.3.890.890","volume":"86","author":"Holler","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2011.02.021_bib0095","doi-asserted-by":"crossref","first-page":"5695","DOI":"10.1200\/JCO.2006.08.0952","volume":"24","author":"Yakoub-Agha","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tracli.2011.02.021_bib0100","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.2000.18.3.537","article-title":"Randomized trial of bone marrow versus lenograstim- primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Soci\u00e9t\u00e9 fran\u00e7aise de greffe de moelle","volume":"18","author":"Blaise","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tracli.2011.02.021_bib0105","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood.V100.9.3128","article-title":"Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study","volume":"100","author":"Mohty","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2011.02.021_bib0110","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJM199708073370602","article-title":"Outcome of cord blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group","volume":"337","author":"Gluckman","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2011.02.021_bib0115","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1182\/blood.V116.21.361.361","article-title":"Interactions between total nucleated and CD34\u00a0cell dose and their impact on outcomes after single and double unrelated cord blood transplantation for patients with hematological malignancies","volume":"116","author":"Michallet","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2011.02.021_bib0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2011.01.006","article-title":"Reduced late mortality risk contributes to similar survival after double unit cord blood transplantation as compared with related and unrelated donor hematopoietic stem cell transplantation","author":"Ponce","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.tracli.2011.02.021_bib0125","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1182\/blood.V116.21.223.223","article-title":"Unrelated cord blood transplantation: comparison after single unit cord blood intrabone injection and double unit cord blood transplantation in patients with hematological malignant disorders. A Eurocord-EBMT Analysis","volume":"116","author":"Rocha","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2011.02.021_bib0130","first-page":"O140","article-title":"Double cord blood cell haematopoietic stem cell transplantation after standard or reduced intensity conditioning: report of the SFGM-TC registry. 35th annual meeting of the EBMT 2009","volume":"43","author":"Labussiere","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.tracli.2011.02.021_bib0135","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1056\/NEJMoa041469","article-title":"Transplants of umbilical cord blood or bone marrow from unrelated donors in adults with acute leukemia. Acute Leukemia Working Party of European Blood and Marrow Transplant Group; Eurocord-Netcord Registry","volume":"351","author":"Rocha","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2011.02.021_bib0140","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/blood-2010-05-285304","article-title":"Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood","volume":"116","author":"Brunstein","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2011.02.021_bib0145","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.beha.2010.06.002","article-title":"Eurocord and Acute Leukemia Working Party of the European Blood and Marrow Transplant Group. Alternative donors hematopoietic stem cells transplantation for adults with acute myeloid leukemia: umbilical cord blood or haplo-identical donors?","volume":"23","author":"Ruggeri","year":"2010","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.tracli.2011.02.021_bib0150","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplant (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2011.02.021_bib0155","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1182\/blood.V84.10.3558.3558","article-title":"DLA-identical bone marrow grafts after low-dose total body irradiation: the effect of canine recombinant hematopoietic growth factors","volume":"84","author":"Storb","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2011.02.021_bib0160","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1083-8791(00)70056-5","article-title":"Intentional induction of mixed chimerism and achievement of antitu- mor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies","volume":"6","author":"Spitzer","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.tracli.2011.02.021_bib0165","first-page":"3101","article-title":"Efficacy of fludarabine as an immunosuppressor for bone marrow transplantation conditioning: preliminary results","volume":"28","author":"Terenzi","year":"1996","journal-title":"Transplant Proc"},{"key":"10.1016\/j.tracli.2011.02.021_bib0170","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","article-title":"Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonma- lignant hematologic diseases","volume":"91","author":"Slavin","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2011.02.021_bib0175","first-page":"78","article-title":"Nonmyeloablative transplants: preclinical and clinical results","volume":"27","author":"Sandmaier","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1016\/j.tracli.2011.02.021_bib0180","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1200\/JCO.1998.16.8.2817","article-title":"Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tracli.2011.02.021_bib0185","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1182\/blood.V89.12.4531","article-title":"Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy","volume":"89","author":"Giralt","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2011.02.021_bib0190","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1182\/blood.V97.3.631","article-title":"Melphalan and purine analog-containing preparative regimens: reduced intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation","volume":"97","author":"Giralt","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2011.02.021_bib0195","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1182\/blood.V94.9.3234","article-title":"Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses","volume":"94","author":"Childs","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2011.02.021_bib0200","first-page":"179","article-title":"Nonmyeloablative allogeneic peripheral blood stem cell transplantation as immunotherapy for malignant diseases","volume":"6","author":"Childs","year":"2000","journal-title":"Cancer J Sci Am"},{"key":"10.1016\/j.tracli.2011.02.021_bib0205","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1182\/blood.V96.7.2419","article-title":"In vivo Campath-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation","volume":"96","author":"Kottaridis","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2011.02.021_bib0210","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1182\/blood.V97.9.2574","article-title":"High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions","volume":"97","author":"Badros","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2011.02.021_bib0215","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s002770000269","article-title":"Antithymocyte globulin as part of the preparative regimen prevents graft failure and severe graft-versus-host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors","volume":"80","author":"Kroger","year":"2001","journal-title":"Ann Hematol"},{"key":"10.1016\/j.tracli.2011.02.021_bib0220","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2000.18.23.3918","article-title":"Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral blood hematopoietic stem cell transplantation as treatment of resistant Hodgkin's disease and non Hodgkin's lymphoma","volume":"18","author":"Carella","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tracli.2011.02.021_bib0225","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood.V99.3.1071","article-title":"Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen","volume":"99","author":"Chakraverty","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2011.02.021_bib0230","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1046\/j.1365-2141.2001.03153.x","article-title":"Allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning: results of a prospective multi-centre study","volume":"115","author":"Martino","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tracli.2011.02.021_bib0235","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.2001.19.14.3340","article-title":"Allogeneic hematopoietic stem cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and post-transplantation factors on outcome","volume":"19","author":"Michallet","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tracli.2011.02.021_bib0240","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/sj.bmt.1702509","article-title":"High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation","volume":"26","author":"Mohty","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.tracli.2011.02.021_bib0245","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.bmt.1703134","article-title":"Reduced intensity conditioning: enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy","volume":"28","author":"Mohty","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.tracli.2011.02.021_bib0250","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","article-title":"Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects","volume":"97","author":"McSweeney","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2011.02.021_bib0255","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1038\/sj.leu.2403105","article-title":"Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen","volume":"17","author":"Mohty","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.tracli.2011.02.021_bib0260","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1182\/blood-2002-12-3629","article-title":"Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen","volume":"102","author":"Mohty","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2011.02.021_bib0265","doi-asserted-by":"crossref","unstructured":"Crocciolo R, Ducastelle, S, Labussi\u00e8re H, Nicolini FE, Thomas X, Barraco F, et al. HLA matching is more critical than CMV matching in predicting non-relapse-mortality of patients undergoing HSCT from an unrelated donor: a retrospective monocenter study. Abstracts of the SFGM-TC congress 2009.","DOI":"10.1182\/blood.V114.22.4336.4336"},{"key":"10.1016\/j.tracli.2011.02.021_bib0270","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/sj.bmt.1705965","article-title":"High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission","volume":"41","author":"Schmid","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.tracli.2011.02.021_bib0275","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood.V100.2.397","article-title":"Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose","volume":"100","author":"Guglielmi","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2011.02.021_bib0280","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/sj.leu.2404481","article-title":"Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2\u00a0concerted action BHM4\u00a0CT98-3936","volume":"21","author":"Br\u00fcggemann","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.tracli.2011.02.021_bib0285","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa074306","article-title":"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia","volume":"358","author":"Schlenk","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2011.02.021_bib0290","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/bmt.2009.155","article-title":"Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44[+]) and T [HLA-DR(+)] cells","volume":"45","author":"Lioznov","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.tracli.2011.02.021_bib0295","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3324\/haematol.12184","article-title":"High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma","volume":"93","author":"El-Cheikh","year":"2008","journal-title":"Haematol"},{"key":"10.1016\/j.tracli.2011.02.021_bib0300","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood-2004-05-2031","article-title":"Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma","volume":"104","author":"Kr\u00f6ger","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2011.02.021_bib0305","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2004-11-4557","volume":"106","author":"Cahn","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2011.02.021_bib0310","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bbmt.2005.09.015","article-title":"A revision of Billingham's tenets: the central role of lymphocyte migration in acute graft-versus-host disease","volume":"12","author":"Sackstein","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.tracli.2011.02.021_bib0315","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1182\/blood-2009-10-249219","article-title":"The impact of anti-HLA antibodies on unrelated cord blood transplantations","volume":"116","author":"Takanashi","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2011.02.021_bib0320","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1182\/blood-2005-09-3741","article-title":"Prognostic significance of NOD2\/CARD15\u00a0variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2\u00a0independent cohorts and may be modulated by the type of gastrointestinal decontamination","volume":"107","author":"Holler","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2011.02.021_bib0325","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cytogfr.2007.10.010","article-title":"Inflammatory cytokines and dendritic cells in acute graft-versus-host disease after allogeneic stem cell transplantation","volume":"19","author":"Mohty","year":"2008","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.tracli.2011.02.021_bib0330","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJM198603203141201","article-title":"Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia","volume":"314","author":"Storb","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2011.02.021_bib0335","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1056\/NEJM198202183060703","article-title":"A randomized study of the prevention of acute graft-versus-host disease","volume":"306","author":"Ramsay","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2011.02.021_bib0340","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1182\/blood.V68.1.119.119","article-title":"Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease","volume":"68","author":"Storb","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2011.02.021_bib0345","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1399-0012.1987.tb00685.x","article-title":"Cyclosporine plus methylprednisolone versus cyclophosphamide plus methylprednisolone as prophylaxis for graft-versus-host disease: a randomized double-blind study in patients undergoing allogeneic marrow transplantation","volume":"1","author":"Santos","year":"1987","journal-title":"Clin Transplant"},{"key":"10.1016\/j.tracli.2011.02.021_bib0350","first-page":"2605","article-title":"A prospective randomized study of acute graft-v-host disease in 107\u00a0patients with leukemia: methotrexate\/prednisone v cyclosporine A\/prednisone","volume":"19","author":"Forman","year":"1987","journal-title":"Transplant Proc"},{"key":"10.1016\/j.tracli.2011.02.021_bib0355","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2141.1989.tb04325.x","article-title":"Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial","volume":"72","author":"Storb","year":"1989","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tracli.2011.02.021_bib0360","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1056\/NEJM198903303201303","article-title":"Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms","volume":"320","author":"Sullivan","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2011.02.021_bib0365","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood.V76.5.1037.1037","article-title":"What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants?","volume":"76","author":"Storb","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2011.02.021_bib0370","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1056\/NEJM199310213291703","article-title":"Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease","volume":"329","author":"Chao","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2011.02.021_bib0375","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1182\/blood.V89.10.3880","article-title":"Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial","volume":"89","author":"Deeg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2011.02.021_bib0380","first-page":"2303","article-title":"Phase III study comparing methotrexate and tacrolimus (prograf FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation","volume":"92","author":"Ratanatharathorn","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2011.02.021_bib0385","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1083-8791(99)70003-0","article-title":"Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-versus-host disease: effect on chronic graft-versus-host disease and long-term survival","volume":"5","author":"Ross","year":"1999","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.tracli.2011.02.021_bib0390","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2005-01-0393","article-title":"Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation","volume":"106","author":"Solomon","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2011.02.021_bib0395","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/sj.cgt.7700076","article-title":"Characterization of anti-tumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells","volume":"6","author":"Ribas","year":"1999","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.tracli.2011.02.021_bib0400","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.bbmt.2003.08.006","article-title":"Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation","volume":"9","author":"Khoury","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.tracli.2011.02.021_bib0405","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood-2002-08-2628","article-title":"Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation","volume":"102","author":"Mielcarek","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2011.02.021_bib0410","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1182\/blood-2007-09-112987","article-title":"Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease","volume":"111","author":"Levine","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2011.02.021_bib0415","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.beha.2008.02.008","article-title":"Diagnosis and manifestations of chronic graft-versus-host disease","volume":"21","author":"Filipovich","year":"2008","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.tracli.2011.02.021_bib0420","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/bmt.2009.307","article-title":"Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation","volume":"45","author":"Shaughnessy","year":"2010","journal-title":"Bone Marrow Transplant"}],"container-title":["Transfusion Clinique et Biologique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782011000577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782011000577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:35:27Z","timestamp":1761129327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1246782011000577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":84,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S1246782011000577"],"URL":"https:\/\/doi.org\/10.1016\/j.tracli.2011.02.021","relation":{},"ISSN":["1246-7820"],"issn-type":[{"value":"1246-7820","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogreffes de cellules souches h\u00e9matopo\u00ef\u00e9tiques","name":"articletitle","label":"Article Title"},{"value":"Transfusion Clinique et Biologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tracli.2011.02.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}